Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma

DISEASE CHARACTERISTICS:

• Histologically confirmed stage IV melanoma

  • Mucosal or ocular melanoma also eligible

• Clinically evaluable disease

  • At least 1 site of measurable disease

PATIENT CHARACTERISTICS:

Age

• 16 and over

Performance status

• ECOG 0-1

Life expectancy

• At least 3 months

Hematopoietic

• WBC at least 2,500/mm\^3
• Absolute neutrophil count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Hemoglobin at least 10 g/dL
• Hematocrit at least 30%

Hepatic

• Bilirubin no greater than upper limit of normal (ULN)* (less than 3.0 mg/dL in patients with Gilbert's syndrome)
• AST no greater than 3 times ULN*
• Hepatitis B surface antigen negative
• Hepatitis C antibody nonreactive
• No evidence or history of significant hepatic disease that would preclude safe administration of high-dose IL-2 NOTE: *Unless attributable to disease

Renal

• Creatinine no greater than 2.0 mg/dL
• No evidence or history of significant renal disease that would preclude safe administration of high-dose IL-2

Cardiovascular

• No evidence or history of significant cardiac disease that would preclude safe administration of high-dose IL-2
• Thallium stress test normal (for patients over 50 years of age or with a history of cardiovascular disease)

Pulmonary

• No evidence or history of significant pulmonary disease that would preclude safe administration of high-dose IL-2

Immunologic

• HIV negative
• No autoimmune disease (including uveitis and autoimmune inflammatory eye disease)
• No active infection

Other

• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix
• No evidence or history of significant gastrointestinal disease that would preclude safe administration of high-dose IL-2
• No evidence or history of psychiatric disease that would preclude safe administration of high-dose IL-2
• No other underlying medical condition that would make the administration of the study drug hazardous or obscure the interpretation of adverse events
• No other concurrent medical condition that would preclude study entry

PRIOR CONCURRENT THERAPY:

Biologic therapy

• At least 3 weeks since prior immunotherapy for melanoma and recovered
• No prior anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody (MDX-CTLA4)
• No prior high-dose (at least 600,000 IU/kg every 8 hours) interleukin-2 (IL-2)

Chemotherapy

• At least 3 weeks since prior chemotherapy for melanoma and recovered
• No concurrent chemotherapy

Endocrine therapy

• At least 3 weeks since prior hormonal therapy for melanoma and recovered
• At least 4 weeks since prior corticosteroids
• No concurrent systemic or topical corticosteroids

Radiotherapy

• At least 3 weeks since prior radiotherapy for melanoma and recovered

Surgery

• Not specified

Other

• No concurrent immunosuppressive agents (e.g., cyclosporine or its analog)